Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (67812)	3/5/2001 10:41:16 AM
From: StockDung	Respond to of 122087

Like I said. Insidetruth.com will be naming names->SEC suspends trade in Ives Health through March 16 WASHINGTON (Reuters) - Federal securities regulators on Monday suspended trading in Ives Health Co. Inc. (IVEH.OB) through March 16, questioning the accuracy of claims the firm has made about an HIV treatment. The Securities and Exchange Commission said in a statement that it issued the suspension because of "questions regarding the accuracy of public statements by Ives Health to investors concerning, among other things, a product being marketed by Ives Health for treatment of human immunodeficiency virus." Ives Health, based in Claremore, Okla., closed at 25 cents on Friday on the OTC bulletin board. Ives was not immediately available for comment. The company has a line of homeopathic medicines and other natural remedies to treat acne, coughs, headaches and sore throat, it said in a recent statement. It is also owns T-Factor, "an all-natural remedy that has been proven to increase T-Cell counts in HIV patients," according to a Feb. 27 statement. The company's Web site is iveshealth.com. 10:12 03-05-01

To: Anthony@Pacific who wrote (67812)	3/5/2001 10:41:16 AM
From: StockDung	Respond to of 122087

Like I said. Insidetruth.com will be naming names->SEC suspends trade in Ives Health through March 16 WASHINGTON (Reuters) - Federal securities regulators on Monday suspended trading in Ives Health Co. Inc. (IVEH.OB) through March 16, questioning the accuracy of claims the firm has made about an HIV treatment. The Securities and Exchange Commission said in a statement that it issued the suspension because of "questions regarding the accuracy of public statements by Ives Health to investors concerning, among other things, a product being marketed by Ives Health for treatment of human immunodeficiency virus." Ives Health, based in Claremore, Okla., closed at 25 cents on Friday on the OTC bulletin board. Ives was not immediately available for comment. The company has a line of homeopathic medicines and other natural remedies to treat acne, coughs, headaches and sore throat, it said in a recent statement. It is also owns T-Factor, "an all-natural remedy that has been proven to increase T-Cell counts in HIV patients," according to a Feb. 27 statement. The company's Web site is iveshealth.com. 10:12 03-05-01